| WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems World Health Organization World Health Organization, 2004 | 481 | 2004 |
| Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. Volume 2. Good manufacturing practices and inspection World Health Organization World Health Organization, 2024 | 229 | 2024 |
| Promoting safety of medicines for children World Health Organization World Health Organization, 2007 | 200* | 2007 |
| Farmacovigilância: um passo em direção ao uso racional de plantas medicinais e fitoterápicos EE Balbino, MF Dias Revista Brasileira de Farmacognosia 20, 992-1000, 2010 | 190 | 2010 |
| Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance Council for International Organizations of Medical Sciences Geneva: WHO/CIOMS, 2012 | 171* | 2012 |
| Rational use of personal protective equipment for COVID-19 and considerations during severe shortages: interim guidance, 23 December 2020 WH Organization World Health Organization, 2020 | 77 | 2020 |
| Global hepatitis report 2024: action for access in low-and middle-income countries World Health Organization World Health Organization, 2024 | 53 | 2024 |
| WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems of medical products: revision VI World Health Organization World Health Organization, 2021 | 52 | 2021 |
| Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings FSL Vianna, L Schüler-Faccini, JCL Leite, SHC de Sousa, LMM da Costa, ... Clinical Dysmorphology 22 (2), 59-63, 2013 | 45 | 2013 |
| Global vaccine safety blueprint: the landscape analysis (survey of regulators) WH Organization World Health Organization, 2012 | 43* | 2012 |
| Uso abusivo de benzidamina no Brasil: uma abordagem em farmacovigilância DM Mota, AA Costa, CS Teixeira, AA Bastos, MF Dias Ciência & Saúde Coletiva 15, 717-724, 2010 | 34* | 2010 |
| Addressing the challenges of regulatory systems strengthening in small states C Preston, MF Dias, J Peña, ML Pombo, A Porrás BMJ Global Health 5 (2), e001912, 2020 | 21 | 2020 |
| WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-seventh report World Health Organization World Health Organization, 2024 | 20 | 2024 |
| Introdução à farmacovigilância MF Dias Storpitis S, Mori ALPM, Yochiy A, Riberio E, Porta V. Ciências farmacêuticas …, 2008 | 17 | 2008 |
| Fontes de notificação em farmacovigilância MF Dias, NR SOUZA, MO BITTENCOURT, MS NOGUEIRA Rev. Farm. Med., São Paulo 34 (6), 2005 | 15 | 2005 |
| Pharmacological Characterization of Sephadex-lnduced Oedema in Rat Paws: Predominant Role of Serotonin and Platelet-Activating Factor JN Francischi, MF Dias, OA Rocha, MS de Abreu Castro, ... International archives of allergy and immunology 109 (4), 398-406, 1996 | 15 | 1996 |
| Guia para notificação de reações adversas em oncologia CS Penido, DA Pereira, DHN Couto, F Schindler, FL Kavalec, GF Escobar, ... Conectfarma Publicações Científicas, 2011 | 13 | 2011 |
| Vigilância sanitária e gerenciamento do risco em medicamento MF Dias, NR Souza, MO Bittencourt, MS Nogueira Fármacos & Medicamentos 2 (3), 1-9, 2007 | 13 | 2007 |
| Barium toxicity after exposure to contaminated contrast solution--Goias State, Brazil, 2003 Centers for Disease Control and Prevention (CDC MMWR. Morbidity and mortality weekly report 52 (43), 1047-1048, 2003 | 11 | 2003 |
| Sim, nós já temos farmacovigilância A BRANDÃO Pharm. Bras, 18-21, 2002 | 8 | 2002 |
Janice E. GrahamTechnoscience and Regulation Research Unit, Dalhousie UniversityVerified email at dal.ca
